Identifying Biomarkers to Predict Immune-checkpoint Therapy Response-is It a Reality or a Distant Dream?

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697699

Authors

Prashanth Ashok Kumar

Affiliations

Soon will be listed here.

References

Ashok Kumar P, Basnet A . The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2023; 12(9):1838-1841. PMC: 10579829. DOI: 10.21037/tlcr-23-566. View

Mok T, Lopes G, Cho B, Kowalski D, Kasahara K, Wu Y . Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023; 34(4):377-388. DOI: 10.1016/j.annonc.2023.01.011. View

Sinha N, Sinha S, Valero C, Schaffer A, Aldape K, Litchfield K . Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. Cancer Res. 2022; 82(11):2076-2083. PMC: 9177633. DOI: 10.1158/0008-5472.CAN-21-2542. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Riely G, Wood D, Ettinger D, Aisner D, Akerley W, Bauman J . Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024; 22(4):249-274. DOI: 10.6004/jnccn.2204.0023. View

Catalano M, Iannone L, Nesi G, Nobili S, Mini E, Roviello G . Immunotherapy-related biomarkers: Confirmations and uncertainties. Crit Rev Oncol Hematol. 2023; 192:104135. DOI: 10.1016/j.critrevonc.2023.104135. View

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

Ashok Kumar P, Karimi M, Basnet A, Seymour L, Kratzke R, Brambilla E . Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data. Clin Lung Cancer. 2023; 24(6):528-540. DOI: 10.1016/j.cllc.2023.06.002. View

Kansanen E, Kuosmanen S, Leinonen H, Levonen A . The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013; 1:45-9. PMC: 3757665. DOI: 10.1016/j.redox.2012.10.001. View

10.

Lu S, Kato T, Dong X, Ahn M, Quang L, Soparattanapaisarn N . Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC. N Engl J Med. 2024; 391(7):585-597. DOI: 10.1056/NEJMoa2402614. View

11.

Herbst R, Garon E, Kim D, Cho B, Gervais R, Perez-Gracia J . Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. J Thorac Oncol. 2021; 16(10):1718-1732. DOI: 10.1016/j.jtho.2021.05.001. View

12.

Ricciuti B, Arbour K, Lin J, Vajdi A, Vokes N, Hong L . Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2021; 17(3):399-410. PMC: 10980559. DOI: 10.1016/j.jtho.2021.10.013. View

13.

OBrien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-1286. DOI: 10.1016/S1470-2045(22)00518-6. View

14.

Jiang Z, Zhou Y, Huang J . A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Front Immunol. 2022; 12:813331. PMC: 8733693. DOI: 10.3389/fimmu.2021.813331. View

15.

Mei T, Wang T, Zhou Q . Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. Clin Exp Med. 2024; 24(1):60. PMC: 10981593. DOI: 10.1007/s10238-024-01324-0. View

16.

Yarchoan M, Albacker L, Hopkins A, Montesion M, Murugesan K, Vithayathil T . PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019; 4(6). PMC: 6482991. DOI: 10.1172/jci.insight.126908. View

17.

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

18.

Schenk E . Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions. Transl Lung Cancer Res. 2023; 12(2):322-336. PMC: 9989807. DOI: 10.21037/tlcr-22-883. View

19.

Tsuboi M, Herbst R, John T, Kato T, Majem M, Grohe C . Overall Survival with Osimertinib in Resected -Mutated NSCLC. N Engl J Med. 2023; 389(2):137-147. DOI: 10.1056/NEJMoa2304594. View

20.

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View